AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Transient receptor potential cation channel subfamily M member 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BX84

UPID:

TRPM6_HUMAN

Alternative names:

Channel kinase 2; Melastatin-related TRP cation channel 6

Alternative UPACC:

Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2

Background:

Transient receptor potential cation channel subfamily M member 6, also known as Channel kinase 2 and Melastatin-related TRP cation channel 6, plays a pivotal role in magnesium homeostasis. It is essential for magnesium absorption in the gut and kidney, functioning as both an ion channel and a serine/threonine-protein kinase.

Therapeutic significance:

The protein is directly linked to Hypomagnesemia 1, a disorder characterized by impaired intestinal magnesium absorption leading to severe neurological symptoms. Understanding its mechanism could pave the way for targeted therapies to correct magnesium imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.